Naltrexone
- Generic Name
- Naltrexone
- Brand Names
- Contrave, Embeda, Vivitrol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23NO4
- CAS Number
- 16590-41-3
- Unique Ingredient Identifier
- 5S6W795CQM
- Background
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
- Indication
Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
- Associated Conditions
- Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
Behavior and Naltrexone Treatment for Alcoholics
- Conditions
- Alcoholism
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Target Recruit Count
- 160
- Registration Number
- NCT00000449
- Locations
- 🇺🇸
Brown University, Center for Alcohol and Addiction Studies, Providence, Rhode Island, United States
Use of Naltrexone in a Clinical Setting
- Conditions
- Alcoholism
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Target Recruit Count
- 300
- Registration Number
- NCT00000445
- Locations
- 🇺🇸
Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, South Carolina, United States
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
- Conditions
- SmokingAlcoholism
- Interventions
- Drug: Placebo Tablet and Nicotine PatchDrug: Placebo Tablet and Placebo Patch
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- The Scripps Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00000437
- Locations
- 🇺🇸
Department of Psychiatry, University of Miami School of Medicine, Miami, Florida, United States
Naltrexone Treatment of Alcohol Dependence
- Conditions
- Alcoholism
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Target Recruit Count
- 240
- Registration Number
- NCT00000452
- Locations
- 🇺🇸
Treatment Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Naltrexone Maintenance Treatment of Alcoholism
- Conditions
- Alcoholism
- Interventions
- Drug: Matched Placebo Tablet
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- The Scripps Research Institute
- Target Recruit Count
- 159
- Registration Number
- NCT00000450
- Locations
- 🇺🇸
Department of Psychiatry, University of Miami School of Medicine, Miami, Florida, United States
Neurobiology of Opioid Dependence: 5 - 5
- Conditions
- Opioid-Related Disorders
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000196
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4
- Conditions
- Alcohol-Related DisordersCocaine-Related Disorders
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000307
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
Neurobiology of Opioid Dependence: 4 - 4
- Conditions
- Opioid-Related Disorders
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000195
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.